产品
编 号：F751308
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2329669-72-7
产品详情
生物活性：
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
体内研究：
XmAb20717 (every two days, for 16 d; NSG mice engrafted with KG1a-luc followed by engraftment with huPBMCs) enhances allogeneic anti-tumor responses in mice.
体外研究：
XmAb20717 has binding avidity and contributes to T cell activation, including IL-2, CD45+ cells, and IFNγ.
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
体内研究：
XmAb20717 (every two days, for 16 d; NSG mice engrafted with KG1a-luc followed by engraftment with huPBMCs) enhances allogeneic anti-tumor responses in mice.
体外研究：
XmAb20717 has binding avidity and contributes to T cell activation, including IL-2, CD45+ cells, and IFNγ.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备